COVID-19 Vaccine Failure in a Patient with Multiple Sclerosis on Ocrelizumab.
B-Cell
COVID-19
humoral immunity
multiple sclerosis
ocrelizumab
vaccination
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
04 Mar 2021
04 Mar 2021
Historique:
received:
17
02
2021
revised:
02
03
2021
accepted:
02
03
2021
entrez:
3
4
2021
pubmed:
4
4
2021
medline:
4
4
2021
Statut:
epublish
Résumé
Vaccines will play a key role in ending the COVID-19 pandemic. Vaccination against infections remains an important part of the management of patients with multiple sclerosis. However, there are limited data about the safety and efficacy of the currently available COVID-19 mRNA vaccines in patients with multiple sclerosis receiving concurrent immunosuppressive therapies. Patients on B cell depleting therapy such as ocrelizumab have an attenuated vaccine response. We report the first case of COVID-19 vaccine failure in a patient with relapsing-remitting multiple sclerosis on B cell depleting therapy, ocrelizumab. We offer suggestions to improve vaccine efficacy in these patients.
Identifiants
pubmed: 33806646
pii: vaccines9030219
doi: 10.3390/vaccines9030219
pmc: PMC8002140
pii:
doi:
Types de publication
Case Reports
Langues
eng
Références
JAMA Neurol. 2020 Sep 1;77(9):1079-1088
pubmed: 32589189
Clin Exp Immunol. 2020 Nov;202(2):149-161
pubmed: 32671831
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Neurology. 2020 Oct 6;95(14):e1999-e2008
pubmed: 32727835
N Engl J Med. 2017 Jan 19;376(3):221-234
pubmed: 28002679
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246